Table 4.
Clinical characteristics of the CKD patients according to quartiles of FGF23 levels
| |
FGF23-Quartile 1 |
FGF23-Quartile 2 |
FGF23-Quartile 3 |
FGF23-Quartile 4 |
|
|---|---|---|---|---|---|
| (n = 47; FGF23, 11–40) | (n = 50; FGF23, 41–63) | (n = 49; FGF23, 64–103) | (n = 49; FG23, 105–2010) | p values | |
| Age (years) |
67.7 ± 14.2 |
68.5 ± 10.6 |
68.2 ± 10.3 |
70.5 ± 10.0 |
0.65 |
| Male |
26 (55) |
33 (66) |
35 (71) |
35 (71) |
0.31 |
| Hypertension |
38 (81) |
37 (74) |
48 (98) |
48 (98) |
<0.01 |
| Diabetes mellitus |
20 (43) |
20 (40) |
29 (59) |
23 (47) |
0.23 |
| Smoking |
23 (49) |
29 (58) |
30 (61) |
28 (57) |
0.66 |
| Dyslipidemia |
35 (74) |
33 (66) |
35 (71) |
43 (88) |
0.06 |
| Body mass index (kg/m2) |
22.2 ± 2.5 |
22.4 ± 5.7 |
22.7 ± 5.4 |
22.7 ± 3.5 |
0.95 |
| Proteinuria (g/day) |
1.2 (0.1-3.3) |
0.7 (0.1-2.6) |
2.2 (0.4-4.0) |
1.2 (0.4-3.6) |
0.14 |
| C-reactive protein (mg/dL) |
0.05 (0.02-0.12) |
0.09 (0.03-0.22) |
0.13 (0.05-0.26) |
0.09 (0.05-0.35)* |
0.01 |
| Hemoglobin (g/dL) |
11.5 ± 2.2 |
11.1 ± 2.1 |
10.6 ± 2.0 |
9.6 ± 1.7** |
<0.01 |
| Serum corrected calcium (mg/dL) |
9.5 ± 0.6 |
9.4 ± 0.5 |
9.5 ± 0.5 |
9.3 ± 0.6 |
0.19 |
| Serum phosphorus (mg/dL) |
3.4 ± 0.5 |
3.5 ± 0.6 |
3.6 ± 0.5 |
4.4 ± 0.9** |
<0.01 |
| Ca-P product (mg2/dL2) |
32.5 ± 5.6 |
33.3 ± 6.0 |
34.4 ± 4.2 |
40.7 ± 8.5** |
<0.01 |
| eGFR (ml/min/1.73m2) |
46.9 (27.0-68.9) |
33.6 (17.3-57.9) |
22.0 (16.0-35.0)** |
12.7 (9.0-17.2)** |
<0.01 |
| CAAC | 23 (49) | 29 (58) | 37 (76) | 39 (80) | <0.01 |
Values are expressed as the means ± SD, number (percent), or median (interquartile range).
CKD chronic kidney disease, FGF fibroblast growth factor, Ca-P calcium-phosphorus, eGFR estimated glomerular filtration rate, CAAC carotid artery calcification.
*p < 0.05, **p < 0.01 vs. FGF23-Quartile 1.